Ab­b­Vie’s trou­bled $10B Ro­va-T can­cer drug pro­gram takes a sud­den turn to­ward the cliff

The Ro­va-T prob­lem at Ab­b­Vie may be head­ed to­ward a full-fledged dis­as­ter.

Re­searchers slammed the brakes on one of their Phase III stud­ies of the $10 bil­lion drug af­ter an in­de­pen­dent group of mon­i­tors de­ter­mined that their drug was linked to a short­er over­all sur­vival rate than the chemo drug used in the con­trol arm.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER